RenovaCare Appoints Alan L. Rubino as President and CEO
RenovaCare, Inc., developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, announced the appointment of Alan L. Rubino as President and Chief Executive Officer. Mr. Rubino will lead the Company through its next stages of clinical and corporate development and financial growth.
“RenovaCare’s patent portfolio and technology platform for organ and tissue regeneration is one of the most compelling opportunities I have seen in this sector in my 35 years of industry experience,” stated Mr. Rubino.
“I look forward to working with the accomplished RenovaCare management team to build value for all our stockholders and bring breakthrough first-in-class regenerative products to market for the benefit of all stakeholders through focused clinical and business development activities in 2020 and beyond.”
Mr. Rubino is recognized for his many accomplishments in major pharmaceutical and small public specialty companies, and industry board positions, that include therapeutics across a broad range of disease areas, including medical devices to accelerate wound healing and tissue regeneration therapies for burns using innovative stem cell technologies.
Recently, Mr. Rubino transitioned from Emisphere Technologies, Inc. after leading a turnaround over the last seven years and helped to position it among the leading global oral drug delivery firms. Emisphere’s turnaround was enhanced by a new four molecule collaboration with Novo Nordisk and anchored by the recent FDA approval of Novo Nordisk’s Rybelsus® which incorporated the company’s carrier technology to introduce the first-ever oral GLP-1 therapeutic for the treatment of diabetes.
The largest part of Mr. Rubino’s distinguished career includes a successful 24 years with Hoffmann-La Roche, now Genentech (a subsidiary of Roche), which is one of the world’s top 10 biopharmaceutical companies. Mr. Rubino led eight large revenue business units (over $1 billion in revenues) and launched the first biologic, Roferon-A® (alfa-interferon 2a). Along with being a member of the US Executive and Operating Committees of Roche, Mr. Rubino presided over 20 new product launches, ranging from dermatology, organ transplantation, oncology, infectious diseases, CNS and other therapeutic areas. In addition, he also played a leading executive role in the acquisitions of Syntex Laboratories and Boehringer Mannheim.
Mr. Rubino holds a B.A. in economics from Rutgers University, along with a full minor in biology and chemistry and attended multiple executive education programs at Harvard Business School and the University of Lausanne in Switzerland. Currently, Mr. Rubino is also on the board of directors of Vericel, Inc., Sanuwave, Inc., and Genisphere, LLC.
“Less than 12 months ago, my family office invested $15.5 million to significantly advance RenovaCare’s business and to pursue the mission of replacing painful and costly skin grafting surgeries with an ultra-gentle healing mist of one’s own skin cells with our SkinGun,™” stated Mr. Harmel S. Rayat, who resigned as Chief Executive Officer but continues to serve as the Company’s Chairman of the Board.
“Today, as a proud long-term stockholder, I am pleased to welcome Mr. Alan Rubino, a seasoned and proven industry executive with a history of success and multiple product launches in the healthcare sector. His appointment is among the most exciting inflection points in recent memory.”